AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
210.26
+3.79 (1.84%)
At close: Apr 14, 2026, 4:00 PM EDT
210.00
-0.26 (-0.12%)
After-hours: Apr 14, 2026, 7:30 PM EDT
AbbVie Revenue
In the year 2025, AbbVie had annual revenue of $61.16B with 8.57% growth. AbbVie had revenue of $16.62B in the quarter ending December 31, 2025, with 10.04% growth.
Revenue (ttm)
$61.16B
Revenue Growth
+8.57%
P/S Ratio
6.08
Revenue / Employee
$1,072,982
Employees
57,000
Market Cap
371.90B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 61.16B | 4.83B | 8.57% |
| Dec 31, 2024 | 56.33B | 2.02B | 3.71% |
| Dec 31, 2023 | 54.32B | -3.74B | -6.44% |
| Dec 31, 2022 | 58.05B | 1.86B | 3.30% |
| Dec 31, 2021 | 56.20B | 10.39B | 22.69% |
| Dec 31, 2020 | 45.80B | 12.54B | 37.69% |
| Dec 31, 2019 | 33.27B | 513.00M | 1.57% |
| Dec 31, 2018 | 32.75B | 4.54B | 16.08% |
| Dec 31, 2017 | 28.22B | 2.58B | 10.06% |
| Dec 31, 2016 | 25.64B | 2.78B | 12.16% |
| Dec 31, 2015 | 22.86B | 2.90B | 14.52% |
| Dec 31, 2014 | 19.96B | 1.17B | 6.23% |
| Dec 31, 2013 | 18.79B | 410.00M | 2.23% |
| Dec 31, 2012 | 18.38B | 936.00M | 5.37% |
| Dec 31, 2011 | 17.44B | 1.81B | 11.55% |
| Dec 31, 2010 | 15.64B | 1.42B | 10.02% |
| Dec 31, 2009 | 14.21B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 96.36B |
| Eli Lilly and Company | 65.18B |
| Merck & Co. | 65.01B |
| Pfizer | 62.58B |
| AstraZeneca | 58.74B |
| Novartis AG | 56.67B |
| Novo Nordisk | 48.59B |
| Bristol-Myers Squibb Company | 48.19B |
ABBV News
- 10 hours ago - Erin Lichy Gets Real About Her Natrelle® Breast Augmentation - PRNewsWire
- 1 day ago - Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain - PRNewsWire
- 2 days ago - AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026 - PRNewsWire
- 6 days ago - AbbVie files lawsuit to address 'outdated' drug discount eligibility program - Reuters
- 6 days ago - BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year - PRNewsWire
- 7 days ago - The price Americans pay for medicine has gotten horribly out of control. Here's how to fix it. - Market Watch
- 7 days ago - Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin - PRNewsWire
- 11 days ago - Swiss industry body says US tariffs on pharmaceuticals will harm patients - Reuters